MY175326A - Product and method for treating diarrhea - Google Patents
Product and method for treating diarrheaInfo
- Publication number
- MY175326A MY175326A MYPI2015703092A MYPI2015703092A MY175326A MY 175326 A MY175326 A MY 175326A MY PI2015703092 A MYPI2015703092 A MY PI2015703092A MY PI2015703092 A MYPI2015703092 A MY PI2015703092A MY 175326 A MY175326 A MY 175326A
- Authority
- MY
- Malaysia
- Prior art keywords
- product
- treating diarrhea
- receptor antagonist
- diarrhea
- treating
- Prior art date
Links
- 206010012735 Diarrhoea Diseases 0.000 title abstract 2
- 239000000938 histamine H1 antagonist Substances 0.000 abstract 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361782608P | 2013-03-14 | 2013-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
MY175326A true MY175326A (en) | 2020-06-19 |
Family
ID=50680150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2015703092A MY175326A (en) | 2013-03-14 | 2014-03-14 | Product and method for treating diarrhea |
Country Status (20)
Country | Link |
---|---|
US (4) | US9717726B2 (de) |
EP (3) | EP3269364B1 (de) |
JP (4) | JP6313417B2 (de) |
KR (4) | KR20180088514A (de) |
CN (2) | CN105324112B (de) |
AU (3) | AU2014239878B2 (de) |
BR (2) | BR112015022513A2 (de) |
CA (1) | CA2906005C (de) |
DK (1) | DK2968205T3 (de) |
ES (2) | ES2743604T3 (de) |
HK (2) | HK1213205A1 (de) |
HU (1) | HUE035201T2 (de) |
IL (3) | IL273377B2 (de) |
MX (2) | MX366329B (de) |
MY (1) | MY175326A (de) |
PL (1) | PL2968205T3 (de) |
PT (1) | PT2968205T (de) |
RU (1) | RU2015143475A (de) |
WO (1) | WO2014152420A2 (de) |
ZA (1) | ZA201708539B (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9717726B2 (en) | 2013-03-14 | 2017-08-01 | Maregade Rx, LLC | Product and method for treating diarrhea |
WO2015073573A1 (en) * | 2013-11-14 | 2015-05-21 | Jacobs Michael M | Compositions and methods for the prevention and treatment of alcohol-induced hangover syndrome |
EP3558296B1 (de) * | 2016-12-23 | 2023-06-28 | Maregade RX, LLC | Niedrigdosisprodukt und verfahren zur behandlung von durchfall |
IT201900012645A1 (it) * | 2019-07-23 | 2021-01-23 | Eros Zanotti | Una composizione farmaceutica per l'uso nel trattamento delle chinetosi |
US11424105B2 (en) * | 2019-08-05 | 2022-08-23 | Hitachi High-Tech Corporation | Plasma processing apparatus |
EP4408414A1 (de) * | 2021-09-22 | 2024-08-07 | Hista RX LLC | Zusammensetzungen und verfahren zur behandlung und prävention von interstitieller zystitis |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5204118A (en) | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
WO1995001792A1 (en) | 1993-07-06 | 1995-01-19 | Merck & Co., Inc. | H2 antagonist-antihistamine combinations |
WO2002043649A2 (en) | 2000-11-30 | 2002-06-06 | The Bio Balance Corp. | Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof |
US6264984B1 (en) * | 1999-12-06 | 2001-07-24 | Bristol-Myers Squibb Company | Effervescent histamine H2 antagonist composition |
US6656492B2 (en) * | 2000-06-30 | 2003-12-02 | Yamanouchi Pharmaceutical Co., Ltd. | Quick disintegrating tablet in buccal cavity and manufacturing method thereof |
DK1451196T3 (da) * | 2001-11-23 | 2007-11-12 | Janssen Pharmaceutica Nv | Anvendelse af substituerede tetracykliske imidazolderivater som antihistaminstoffer |
SE528789C2 (sv) | 2004-09-10 | 2007-02-13 | Sandvik Intellectual Property | PVD-belagt skär av hårdmetall samt sätt att tillverka detta |
US20070077300A1 (en) * | 2005-09-30 | 2007-04-05 | Wynn David W | Oral compositions containing a salivation inducing agent |
US20090312358A1 (en) | 2006-03-22 | 2009-12-17 | Trustees Of Boston University | Method for management of diarrhea |
US8207188B2 (en) | 2006-04-07 | 2012-06-26 | Michalis Nicolaou | Treatment of diseases modulated by a H4 receptor agonist |
US20070254050A1 (en) * | 2006-05-01 | 2007-11-01 | Quart Barry D | Method for treatment of diarrhea-predominant irritable bowel syndrome |
US20090042972A1 (en) * | 2006-05-19 | 2009-02-12 | Somaxon Pharmaceuticals, Inc. | Methods of using low-dose doxepin for the improvement of sleep |
EP2170317A4 (de) | 2007-02-12 | 2011-03-23 | Mike Nicolaou | Behandlung von copd, gastroösophagealer reflux-krankheit (gerd), lebensmittelallergien und anderen gastrointestinalen erkrankungen und störungen, die durch richtiges histamin-management gelindert werden, mit einer kombination von histidindecarboxylase-hemmern, lra-arzneimitteln und/oder anti-h2-arzneimitteln |
US20090074862A1 (en) * | 2007-04-13 | 2009-03-19 | Luigi Schioppi | Low-dose doxepin formulations and methods of making and using the same |
US8263581B2 (en) | 2009-07-03 | 2012-09-11 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
EP2920306B1 (de) | 2012-11-13 | 2018-06-27 | Codiak BioSciences, Inc. | Freisetzung eines therapeutischen mittels |
US9717726B2 (en) * | 2013-03-14 | 2017-08-01 | Maregade Rx, LLC | Product and method for treating diarrhea |
EP3558296B1 (de) | 2016-12-23 | 2023-06-28 | Maregade RX, LLC | Niedrigdosisprodukt und verfahren zur behandlung von durchfall |
-
2014
- 2014-03-13 US US14/209,937 patent/US9717726B2/en active Active
- 2014-03-14 CN CN201480022471.0A patent/CN105324112B/zh active Active
- 2014-03-14 CN CN201810755897.7A patent/CN108939076A/zh active Pending
- 2014-03-14 MX MX2017011532A patent/MX366329B/es unknown
- 2014-03-14 DK DK14722445.5T patent/DK2968205T3/da active
- 2014-03-14 KR KR1020187021688A patent/KR20180088514A/ko not_active IP Right Cessation
- 2014-03-14 HU HUE14722445A patent/HUE035201T2/hu unknown
- 2014-03-14 EP EP17189072.6A patent/EP3269364B1/de active Active
- 2014-03-14 CA CA2906005A patent/CA2906005C/en active Active
- 2014-03-14 BR BR112015022513A patent/BR112015022513A2/pt not_active Application Discontinuation
- 2014-03-14 RU RU2015143475A patent/RU2015143475A/ru not_active Application Discontinuation
- 2014-03-14 KR KR1020157029028A patent/KR101884506B1/ko active IP Right Grant
- 2014-03-14 MX MX2015011885A patent/MX350814B/es active IP Right Grant
- 2014-03-14 PT PT147224455T patent/PT2968205T/pt unknown
- 2014-03-14 WO PCT/US2014/027323 patent/WO2014152420A2/en active Application Filing
- 2014-03-14 KR KR1020217004881A patent/KR102449977B1/ko active IP Right Grant
- 2014-03-14 KR KR1020207023569A patent/KR20200100211A/ko not_active Application Discontinuation
- 2014-03-14 ES ES17189072T patent/ES2743604T3/es active Active
- 2014-03-14 EP EP19169633.5A patent/EP3581205A3/de active Pending
- 2014-03-14 ES ES14722445.5T patent/ES2655505T3/es active Active
- 2014-03-14 JP JP2016502404A patent/JP6313417B2/ja active Active
- 2014-03-14 MY MYPI2015703092A patent/MY175326A/en unknown
- 2014-03-14 BR BR122017004716-7A patent/BR122017004716A2/pt not_active Application Discontinuation
- 2014-03-14 PL PL14722445T patent/PL2968205T3/pl unknown
- 2014-03-14 AU AU2014239878A patent/AU2014239878B2/en active Active
- 2014-03-14 EP EP14722445.5A patent/EP2968205B1/de active Active
- 2014-03-14 IL IL273377A patent/IL273377B2/en unknown
-
2015
- 2015-09-09 IL IL241372A patent/IL241372B/en active IP Right Grant
-
2016
- 2016-02-04 HK HK16101359.5A patent/HK1213205A1/zh unknown
- 2016-09-06 US US15/257,674 patent/US10034875B2/en active Active
-
2017
- 2017-10-24 AU AU2017251701A patent/AU2017251701B2/en active Active
- 2017-12-13 IL IL256300A patent/IL256300B/en active IP Right Grant
- 2017-12-15 ZA ZA2017/08539A patent/ZA201708539B/en unknown
-
2018
- 2018-03-22 JP JP2018054088A patent/JP6473254B2/ja active Active
- 2018-05-28 HK HK18106976.5A patent/HK1247557B/zh unknown
- 2018-07-06 US US16/029,384 patent/US11058681B2/en active Active
-
2019
- 2019-01-24 JP JP2019009896A patent/JP6790140B2/ja active Active
- 2019-02-28 AU AU2019201412A patent/AU2019201412A1/en not_active Abandoned
-
2020
- 2020-11-04 JP JP2020184294A patent/JP2021046400A/ja active Pending
-
2021
- 2021-05-28 US US17/333,525 patent/US20220047583A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL286808A (en) | System and methods for ocular injection | |
MX2015009106A (es) | Composiciones de solución sólida y su uso en el tratamiento del dolor intenso. | |
AU357122S (en) | Headgear for patient interface | |
SG2013022967A (en) | Method and generator for hydrogen production | |
AU355322S (en) | Chair | |
MY175326A (en) | Product and method for treating diarrhea | |
SA516370641B1 (ar) | مركبات حلقية غير متجانسة وطرق لاستخدامها | |
GB201306350D0 (en) | Apparatus and methods for key generation | |
EP2983625C0 (de) | Selbstschliessende vorrichtungen sowie einrichtung und verfahren zur herstellung und ausgabe davon | |
EP2968345A4 (de) | Duale mek/pi3k-hemmer und therapeutische verfahren damit | |
SG11201604626VA (en) | Medicament apparatus and method | |
AU350280S (en) | Apparatus for skin treatment | |
EP2948669A4 (de) | Brennstoffbehandlungsvorrichtung | |
GB2526490B (en) | Feed delivery system and method for gasifier | |
MX2015013021A (es) | 5-bromo-indirrubinas. | |
PH12017500923A1 (en) | New dosage and use of a a2a antagonist | |
MX368870B (es) | Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas. | |
EP3080246A4 (de) | Zusammensetzungen und verfahren zur herstellung und verabreichung von braunen adipozyten | |
IL248962A0 (en) | Device and method for administering drugs to the brain | |
MX2016016667A (es) | Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer. | |
IN2013MU01111A (de) | ||
MX2016011706A (es) | Formulaciones de progesterona. | |
NZ631749A (en) | Methods of treating cancer using angiogenin or an angiogenin agonist | |
SG11201808894RA (en) | Injection device | |
MX2017012449A (es) | Tratamiento del dolor. |